The estimated Net Worth of John E. And Lois A. Rogers is at least 3.31 百万$ dollars as of 20 April 2015. John Rogers owns over 17,500 units of Aduro BioTech stock worth over 3,314,427$ and over the last 10 years John sold ADRO stock worth over 0$.
John has made over 2 trades of the Aduro BioTech stock since 2015, according to the Form 4 filled with the SEC. Most recently John bought 17,500 units of ADRO stock worth 297,500$ on 20 April 2015.
The largest trade John's ever made was buying 147,058 units of Aduro BioTech stock on 20 April 2015 worth over 2,499,986$. On average, John trades about 82,279 units every 0 days since 2015. As of 20 April 2015 John still owns at least 33,649 units of Aduro BioTech stock.
You can see the complete history of John Rogers stock trades at the bottom of the page.
John's mailing address filed with the SEC is C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY, CA, 94710.
Over the last 10 years, insiders at Aduro BioTech have traded over 5,295,750$ worth of Aduro BioTech stock and bought 614,134 units worth 10,440,278$ . The most active insiders traders include William Mariner Greenman、Stephen T Isaacs、Thomas W. Dubensky. On average, Aduro BioTech executives and independent directors trade stock every 11 days with the average trade being worth of 2,189,064$. The most recent stock trade was executed by Stephen T Isaacs on 15 September 2020, trading 32,481 units of ADRO stock currently worth 77,630$.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
Aduro BioTech executives and other stock owners filed with the SEC include: